

PRESS RELEASE



TheraVet announces the commercial launch of BIOCERA-VET

- ***BIOCERA-VET: an injectable bone cement of new generation promoting bone formation and consolidation for small pets.***
- ***Initial commercialization in Belgium with the ambition to quickly extend to France, the Netherlands, and in the longer term, to the rest of Europe.***

Jumet (Wallonia, Belgium), April 1st, 2021 - **TheraVet S.A.**, a pioneering company in the management of osteoarticular diseases in pets, **announced today the commercial launch of BIOCERA-VET, its new generation bone substitute for the treatment of bone surgeries in small companions.** BIOCERA-VET will initially be commercialized on the Belgian orthopedic market and will quickly be extended to France and the Netherlands.

A better quality of life for pets: a driving force of the orthopedic veterinary market

Due to the growing importance of pets and of their quality of life for their owners, animal health is becoming more and more a social and medical issue. With an increase of life expectancy, the ageing of the animal added to age-related pathologies such as obesity, owners' awareness to effective animal care¹ has quickly developed these past years, creating an acceleration in treatments availability. Thus, the veterinary orthopedic market has been growing steadily for several years (7.5% expected for the next 7 years).

¹ *Veterinary Orthopedics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026) – Mordor Intelligence: <https://www.mordorintelligence.com/industry-reports/veterinary-orthopedics-market>*

Just like their owners, small pets can suffer of several musculoskeletal pathologies linked to traumatic injuries (fractured bone for example), ligament rupture or other diseases such as limb deformities.

Management of these orthopedic conditions may require bone grafting to enhance healing in fracture with delayed bone consolidation, arthrodesis, or osteotomy, to treat major defects with substantial bone loss or to fill in cavities².

Despite the recent interest in research for medical and therapeutic innovations in animal health, that approved the use of alternatives to natural bone like allograft³-based and synthetic products, autologous⁴ bone graft is still considered as the standard of procedure. However, this procedure present major disadvantages such a donor site morbidities and lameness, limited availability of graft volume, particularly in small size pets, and additional surgical time.

Therefore, there is a real need for new bone substitute alternatives to replace effectively autologous bone graft in orthopedics surgeries.

BIOCERA-VET: an innovative alternative to autologous bone graft available in a major part of Europe

From today, TheraVet will start commercialization of its BIOCERA-VET product in Belgium. Other countries such as France and the Netherlands will quickly follow. The Company's ambition is to extend further in the European Market later in 2021 and in the beginning of 2022.

BIOCERA-VET is a new bone substitute that is indicated in bone surgeries where a need of bone grafting is present such as arthrodesis, complex fractures, corrective osteotomy used in correction of limb deformities or as add-on to Tibial Tuberosity Advancement⁵ (TTA).

BIOCERA-VET is an injectable synthetic self-hardening calcium-phosphate cement combining osteo-inductive, osteo-conductive and osteo-integrative properties to support **a fast and strong consolidation**. BIOCERA-VET also presents **an excellent safety profile** thanks to its complete biocompatibility, **reduced comorbidities and superior ergonomics** allowing to save a significative surgical time compared to other procedures.

« *BIOCERA-VET is a unique product in veterinary orthopedics which ergonomics presents a real advantage as compared to autograft* » **said Dr Olivier Stiévenart, vet orthopedic surgeon at Surgivet in Belgium.** « *Using BIOCERA-VET has enabled us to optimize our*

² DeCamp, C. E., Johnston, S. A., Déjardin, L. M., & Schaefer, S. L. (2016). Bone grafting. Brinker, Piermattei and Flo's Handbook of Small Animal Orthopedics and Fracture Repair, 153–162. doi:10.1016/b978-1-4377-2364-9.00012-4

³ Allograft is defined as the use of grafts obtained from donor individual

⁴ Autologous bone graft is defined as the use of bone obtained from the same individual receiving the graft

⁵ TTA: surgical treatment of cranial cruciate ligament rupture

patient care considerably, by reducing the operating time by at least 30 minutes. The use of an efficient and rapid bone substitute represents a real progress in terms of both operations and the animal's quality of life».

Julie Schurgers, Chief Commercial Officer of TheraVet, concluded: «*BIOCERA-VET is a unique product on the veterinary bone substitute market, combining outstanding bone consolidation properties with an excellent safety profile and superior ergonomics. We are very excited today to announce its commercialization on the market and are convinced that this innovative product will significantly improve the daily practices of veterinarians, for the well-being of patients and their owners. »*



About BIOCERA-VET

BIOCERA-VET is a line of injectable synthetic self-hardening calcium-phosphate bone substitutes. BIOCERA-VET, a new veterinary medical device, presents unique properties combining ideal bone formation and remodeling properties associated to mechanical resistance. BIOCERA-VET targets bone surgeries (such as arthrodesis, fractures) and osteosarcoma in small companions (dogs and cats) and bone cyst in horses.

For more info, www.thera.vet/en/biocera-vet or www.covetrus.be

About TheraVet

TheraVet is a vet company created in November 2017 by Enrico Bastianelli, MD, MBA, and based in Jumet, Belgium. The Company specializes in the treatment of osteoarticular diseases in small companion animals, such as dogs, thanks to its portfolio of biological and synthetic products. TheraVet currently has two product lines: BIOCERA-VET, a line of injectable synthetic self-hardening high porosity calcium-phosphate bone substitutes and VISCO-VET, a versatile line of injectable hyaluronan-based visco-regenerative gel with anti-inflammatory and pro-regenerative properties.

Contact us at info@thera.vet, on TheraVet's [LinkedIn](#) or via www.thera.vet

Media Contacts

NewCap

Arthur Rouillé

arouille@newcap.fr

+33 (0)1 44 71 00 15

TheraVet S.A.

11b rue d'Edimbourg

6040 Jumet

Belgique

TheraVet USA

1716 Briarcrest Dr. Suite 714

Bryan, Texas, 77802

USA